Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350528 | 0.80 | TAAR1 (0.36) | DPP4HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL15819889 | 0.80 | TAAR1 (0.36) | DPP4HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL4649158 | 0.77 | ALDH1A1 (0.41) | DPP4TAAR1LOXL2 | |
| SCHEMBL29912653 | 0.74 | LMNA (0.33) | DPP4TAAR1 | |
| SCHEMBL22829991 | 0.74 | LMNA (0.33) | DPP4TAAR1 | |
| SCHEMBL17048709 | 0.73 | TAAR1 (0.54) | HTR2AHTR2CSLC6A4HTR2BTAAR1 | |
| SCHEMBL29674856 | 0.72 | ALDH1A1 (0.43) | GAACYP3A4 | |
| SCHEMBL9387233 | 0.72 | ALDH1A1 (0.43) | GAACYP3A4 | |
| SCHEMBL4704877 | 0.72 | ALDH1A1 (0.43) | GAACYP3A4 | |
| SCHEMBL4929798 | 0.72 | GAA (0.41) | GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957481-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062817-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | TPMT, MALT1, THPO | DPP4 1619/4885GAA 3966/4885HTR2A 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.